Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

Overview of attention for article published in Blood, June 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 1 news outlet
twitter: 9 X users

patent: 1 patent

Readers on

mendeley: 101 Mendeley

Summary News X Patents

So far, Altmetric has seen 1 patent that references this research output.

SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT

Application WO-2024040132-A2

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.